A 30‑year‑old woman taking sertraline 75 mg daily presents with new onset decreased libido. How should her sexual dysfunction be managed?

Management of Sertraline-Induced Decreased Libido in a 30-Year-Old Woman

Switch to bupropion as first-line therapy, as it has significantly lower rates of sexual dysfunction (8-10%) compared to sertraline (14% in males, 6% in females), and is specifically recommended by the American College of Physicians when sexual dysfunction occurs with SSRI treatment. 1

Evidence-Based Treatment Algorithm

First-Line Strategy: Switch to Bupropion

• Bupropion is the preferred alternative when sertraline causes sexual dysfunction, with sexual side effect rates of only 8-10% versus sertraline's 14% (males) and 6% (females). 1, 2
• The American College of Physicians explicitly recommends bupropion as first-line therapy when sexual function is a major concern. 1, 2
• Bupropion should not be used if the patient has a seizure disorder or is significantly agitated. 1
• Taper sertraline gradually over 10-14 days to avoid withdrawal symptoms before initiating bupropion. 1

Second-Line Strategy: Switch to Mirtazapine

• If bupropion is contraindicated or fails, switch to mirtazapine 15-30 mg at bedtime, which has minimal to no sexual side effects and may actually improve sexual function. 1, 2
• Mirtazapine causes sedation and weight gain, which can be therapeutically beneficial for patients with insomnia or poor appetite but may be undesirable for others. 1, 2
• This option is particularly useful if the patient has comorbid insomnia or poor appetite. 1

Third-Line Strategy: Dose Reduction

• If switching medications is not feasible, reduce sertraline to the minimum effective dose for depression control, as sexual side effects are strongly dose-dependent. 1
• However, this strategy risks inadequate depression control and is less preferred than switching. 1

Important Clinical Caveats

What NOT to Do

• Do not use buspirone to manage SSRI-induced sexual dysfunction—there is no evidence supporting its effectiveness for this indication. 1
• Avoid paroxetine entirely if switching to another SSRI is considered, as it has the highest sexual dysfunction rate among all SSRIs at 70.7%. 1, 2
• Do not simply wait for spontaneous remission, as sexual dysfunction typically persists with continued SSRI use. 3, 4

Monitoring and Follow-Up

• Begin monitoring for therapeutic response and adverse effects within 1-2 weeks of medication change. 1, 2
• Modify treatment if no adequate response is seen within 6-8 weeks. 1, 2
• Directly and routinely inquire about sexual side effects, as patients seldom volunteer this information and clinical trials vastly underreport the true incidence. 1

Additional Evaluation

• Check morning total testosterone levels (>300 ng/dL) to rule out hypogonadism as a contributing factor, since low testosterone can cause decreased libido independent of SSRI effects. 1
• Screen for other medical contributors including diabetes, cardiovascular disease, and concomitant medications that may impair libido. 1
• Consider referral to a sexual health specialist if symptoms persist despite medication changes. 1

Special Population Considerations

• If this patient were on tamoxifen for breast cancer, avoid bupropion, paroxetine, or fluoxetine due to CYP2D6 inhibition reducing tamoxifen efficacy; instead use venlafaxine or citalopram. 1, 2

Non-Pharmacologic Adjuncts

• Consider referral for sex therapy or couples counseling to help develop strategies for managing sexual changes. 1
• Vibratory therapy can enhance orgasm intensity if loss of genital sensation is present. 1
• Pelvic floor physical therapy may address coexisting pelvic floor dysfunction. 1